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Summary (117 words) 16 
Cytomegalovirus is an ubiquitous herpesvirus that causes silent-to-mild infections in 17 
healthy individuals, and potentially fatal infections in the immunocompromised, 18 
especially paediatric patients. CMV reactivation during periods of intense immune 19 
suppression is associated with significant economic costs and poor patient outcomes. 20 
With a limited range of drugs licensed to treat CMV reactivation, managing antiviral 21 
resistance is vital. In research settings, high-throughput sequencing is superseding 22 
PCR-based monitoring of resistance mutations, revealing a more complicated – and 23 
more informative – picture of emerging mutation profiles in clinical samples. In the next 24 
decade, it is foreseeable that CMV whole genome sequencing for management of 25 
antiviral drug resistance will become as important for personalised patient care as 26 
qPCR monitoring of virus loads is today. 27 
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Main text (1459/1500 words) 28 
Cytomegalovirus (CMV) is a common human pathogen causing life-long infection. In 29 
immunocompetent individuals, this double stranded betaherpesvirus causes a silent or 30 
mild primary infection, occasionally causing an infectious mononucleosis-like illness. In 31 
individuals with iatrogenic, acquired or inborn immunodeficiency, CMV has the capacity 32 
to cause a range of diseases. These include pneumonitis, colitis, CNS disease, and 33 
ocular manifestations such as retinitis and uveitis; the more severe forms of CMV 34 
disease can be fatal. 35 
Paediatric patients may be at risk of severe CMV infections for a number of reasons. 36 
There is data to suggest that while the paediatric CD8+ T cell response to primary CMV 37 
infection is similar to that of adults [1], the CD4+ response is not as effective as the adult 38 
response [2]. Primary CMV infections in infants leads to prolonged shedding of the virus 39 
in urine and saliva which is not seen in adults [3], with the result that infants may 40 
present a significant infection risk to their siblings and other children they interact with 41 
closely, as well as CMV-negative adults. 42 
There are four major categories of paediatric patient in whom serious CMV disease is 43 
commonly reported. Congenital CMV infection occurs in ~0.5% of live births, with the 44 
greatest risk found in mothers who are infected with CMV for the first time during 45 
pregnancy. Children and adults with HIV are at significant risk of CMV disease due to 46 
poor T cell control of this virus. Reduced T cell function contributes to the increased risk 47 
of CMV disease in organ transplant recipients, as intense immune suppression is 48 
required to prevent graft rejection. Finally, inborn errors of immunity and conditions 49 
leading to poor thymus development also put children at risk of serious CMV infections 50 
and disease. CMV is therefore a significant pathogen in many areas of paediatric 51 
medicine.  52 
The burden of drug resistance in cytomegalovirus disease 53 
There are five drugs available for treatment of CMV (ganciclovir, cidofovir, foscarnet, 54 
maribavir and letermovir), and a number of other drugs used off-label to treat CMV 55 
disease, such as leflunomide and artesunate. These drugs may be given 56 
3 
 
prophylactically to prevent CMV reactivation, or pre-emptively to treat emerging CMV 57 
disease, but either approach requires weeks to months of antiviral therapy. These drugs 58 
have significant side-effect profiles of their own, creating a risk that antiviral treatment 59 
may need to be reduced or stopped. Some CMV antivirals poorly penetrate certain 60 
tissue compartments. Both factors increase the likelihood of paediatric patients being 61 
exposed to sub-therapeutic drug doses, a risk factor for emergence of antiviral 62 
resistance.  63 
The economic burden of CMV reactivation in the setting of paediatric transplantation, 64 
especially haemopoetic stem cell transplant (HSCT), has been calculated as up to 65 
£22,500 (~$34,000) per patient, as well as CMV disease increasing the risk of graft 66 
rejection in solid organ transplant recipients [4, 5]. A recent study found that pre-emptive 67 
antiviral treatment led to 14.5% of CMV-positive haplo-HSCT recipients developing 68 
antiviral resistance mutations [5]. Ensuring timely and effective delivery of antivirals and 69 
preventing resistance is also important for long-term patient outcomes in congenitally 70 
infected neonates. Antiviral therapy can reduce or prevent many of the long-term 71 
sequelae of congenital CMV infection, including sensorineural hearing loss [6]. Given 72 
the small pool of antiviral options currently available to clinicians, there are compelling 73 
clinical and financial reasons to better manage CMV drug resistance. 74 
Monitoring CMV drug resistance 75 
Unlike many pathogenic bacteria, it is time consuming and expensive to culture CMV 76 
and test its drug-resistance phenotype by plaque assay. Fortunately, there is a growing 77 
catalogue of known drug resistance mutations [7, 8] in the genes targeted by 78 
ganciclovir, foscarnet and cidofovir: UL54 and UL97.  79 
The primary approach to genetically confirming a clinical suspicion of antiviral 80 
resistance has been to PCR amplify and Sanger sequence small regions of these 81 
genes, which can be achieved directly from clinical samples. This method has 82 
successfully identified hundreds of mutations which may convey resistance to one or 83 
more drugs (and their prodrugs or oral derivatives). Traditional small sequencing of 84 
these PCR products is relatively inexpensive, but cannot be easily scaled over the 85 
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growing number of genes, widely distributed over CMV’s large (~230kb) genome, on 86 
which new anti-CMV drugs act. It is also limited to detecting resistance mutations which 87 
reach frequencies of greater than ~20%. 88 
PCR amplification of CMV fragments has increasingly being combined with high-89 
throughput sequencing technologies. Amplicons are sequenced to high depth using a 90 
variety of next-generation sequencing platforms. This approach detects resistance 91 
mutations sooner, at lower frequencies, than Sanger sequencing of PCR products, with 92 
studies reporting detection of resistance mutations at frequencies of 3% [9, 10]. 93 
Unfortunately, as with Sanger sequencing, this approach still relies on labour-intensive 94 
PCR for the growing number of genes targeted by new antivirals and other therapies.  95 
Novel approaches are being developed which can sequence whole CMV genomes, or 96 
genes of interest, without the need for PCR or virus isolation and culture. Using 97 
technology developed for human whole-exome capture and pull down, methods such as 98 
SureSelect (Agilent) or SeqCap (Nimblegen) can be used to sequence virus genomes 99 
to high depth directly from clinical samples. SureSelect uses custom baits to capture 100 
CMV sequences and enrich them in the DNA that forms a sequencing library. This 101 
approach has been very successful in sequencing relatively low virus load samples for 102 
other herpesviruses [11, 12], and allows antiviral resistance mutations to be monitored 103 
even as circulating CMV populations in blood, urine or CSF decline to low levels.  104 
The future of CMV disease management 105 
It is recognised that there is no unified strategy in place for monitoring the emergence of 106 
CMV drug resistance in immunocompromised paediatric patients [13]. Clinical trials of 107 
antiviral drugs are typically performed in adults rather than children. Choosing which 108 
drugs to treat with, for what duration and dose, and managing clinically suspected drug 109 
resistance is therefore even more challenging in paediatric patients than in adults [14].  110 
Further studies are needed to establish at what frequency a resistance mutation must 111 
be present to warrant clinical action. Published data suggests that resistance mutations 112 
seen at high frequencies at the point of clinical diagnosis of resistance can be detected 113 
weeks earlier by deep sequencing, at frequencies <10% [10]. Researchers and 114 
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clinicians need data on whether, in the presence of a low-frequency drug resistance 115 
mutation, modifying an existing treatment schedule to increase the dosage or change 116 
drug delivery method to achieve better tissue penetration is a viable treatment option. 117 
Deep-sequencing studies of the evolution of antiviral resistance in CMV disease also 118 
highlight the need for new drugs which target different parts of the CMV genome to 119 
avoid the emergence of cross-resistant variants. Given the occurrence of single 120 
nucleotide variants which convey resistance to more than one drug, multi-drug resistant 121 
CMV is a known phenomenon [10]. At present, clinical sequencing may reveal that a 122 
patient’s circulating CMV strain or strains are already resistant to all available treatment 123 
options. In the future, if drugs such as artesunate, leflunomide and letermovir are more 124 
widely used [15], sequence data could inform a clinical decision to switch to drugs which 125 
act on different CMV genes. By using these new drugs, clinicians may be able to avoid 126 
the problem of pre-existing cross-resistance in previously treated patients, a significant 127 
problem for drugs which target UL54 and UL97. 128 
Adoptive immunotherapy is a further weapon in the CMV management arsenal, infusing 129 
the host with CMV-specific cytotoxic T cells, and it may one day reduce reliance on 130 
antivirals [16]. It is also likely to drive CMV evolution, selecting for CMV epitopes which 131 
escape the infused T cells. These mutations will expand the number of genes which 132 
need to be sequenced in order to manage CMV infection in immunocompromised 133 
patients. It will rapidly become intractable to use PCR-based methods of CMV 134 
sequencing, if this point has not already been reached. The future of CMV management 135 
will require whole-genome sequencing and analysis of circulating CMV strains within 136 
each patient. This will in turn create a need for automated, scalable solutions for 137 
monitoring CMV genome variation, as the current bioinformatic burden of sequence 138 
analysis is a limiting factor in reducing the turn-around times from sample to 139 
personalised drug-resistance profile.  140 
Future perspective 141 
While the majority of immunocompromised paediatric patients with CMV infections are 142 
successfully treated with standard approaches to CMV load monitoring (qPCR) and 143 
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prophylactic or preemptive antiviral treatment, clinicians cannot currently predict which 144 
patients will fail first-line therapies due to pre-existing resistance mutations or progress 145 
to multidrug-resistant CMV infections. Prospective and regular sequencing of CMV, 146 
particularly in patients who have already been treated with drugs with anti-CMV activity, 147 
is likely to become the new gold standard in virological monitoring within the near future. 148 
To achieve this goal, existing sequencing and analysis methods must be made scalable 149 
and automatable to reduce costs and turn-around times, and bring this technology into a 150 
healthcare laboratory setting. 151 
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